CIM Investment Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$317K Hold
14,239
0.08% 189
2025
Q4
$380K Hold
14,239
0.1% 158
2025
Q3
$304K Sell
14,239
-15,334
-52% -$363K 0.08% 178
2025
Q2
$589K Buy
29,573
+14,841
+101% +$276K 0.11% 162
2025
Q1
$245K Sell
14,732
-350
-2% -$6.36K 0.06% 199
2024
Q4
$277K Hold
15,082
0.08% 195
2024
Q3
$232K Hold
15,082
0.07% 211
2024
Q2
$245K Sell
15,082
-3,588
-19% -$57.9K 0.08% 203
2024
Q1
$345K Buy
18,670
+8,418
+82% +$209K 0.1% 188
2023
Q4
$321K Hold
10,252
0.1% 184
2023
Q3
$214K Hold
10,252
0.08% 238
2023
Q2
$246K Buy
+10,252
New +$228K 0.08% 222
2018
Q4
Sell
-13,593
Closed -$282K 297
2018
Q3
$282K Sell
13,593
-1,279
-9% -$20.1K 0.1% 281
2018
Q2
$227K Buy
+14,872
New +$265K 0.08% 317
2017
Q3
Sell
-8,807
Closed -$246K 316
2017
Q2
$246K Sell
8,807
-276
-3% -$8.22K 0.09% 317
2017
Q1
$312K Hold
9,083
0.11% 256
2016
Q4
$262K Hold
9,083
0.1% 287
2016
Q3
$289K Buy
9,083
+350
+4% +$11.9K 0.11% 252
2016
Q2
$283K Buy
+8,733
New +$292K 0.12% 226
2015
Q1
Sell
-6,340
Closed -$201K 258
2014
Q4
$201K Buy
+6,340
New +$180K 0.09% 237

Other funds holding ACAD

CIM Investment Management's ACAD Position: Q1 2026 in Review

CIM Investment Management held its Acadia Pharmaceuticals (ACAD) position steady in Q1 2026 at 14,239 shares worth $317K. The position accounts for 0.08% of the portfolio, ranked #189.

CIM Investment Management first reported a position in ACAD in Q4 2014 and has held it in 20 quarters since. The position peaked at $589K in Q2 2025. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • CIM Investment Management held 14,239 shares of Acadia Pharmaceuticals worth $317K as of Q1 2026.
  • CIM Investment Management left its Acadia Pharmaceuticals share count unchanged in Q1 2026.
  • Acadia Pharmaceuticals made up 0.08% of CIM Investment Management's portfolio in Q1 2026, its #189 holding.
  • CIM Investment Management first reported a position in Acadia Pharmaceuticals in Q4 2014 and has held it in 20 quarters since.
  • CIM Investment Management's Acadia Pharmaceuticals position peaked at $589K in Q2 2025.
  • 340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on CIM Investment Management's 13F filing for Q1 2026, filed 19 May 2026.